Midodrine for female incontinence: a preliminary report.
Twenty-six women (aged 26 to 60) with stress incontinence underwent urodynamic investigation before and after oral administration of 5 mg of midodrine, a new adrenergic agent with alpha-stimulant activity. A significant increase in maximum urethral closing pressure combined with a nonsignificant increase in flow time and maximum flow was observed after treatment.
D000328:Adult; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D008879:Midodrine / Q000627:therapeutic use*; D014521:Urethra / Q000187:drug effects; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
D004983:Ethanolamines; D008879:Midodrine